Trial Profile
Phase I/II Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ralimetinib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms GLYRad
- 13 Aug 2019 Status changed from active, no longer recruiting to completed.
- 28 Nov 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Jun 2019.
- 09 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2018.